Evidence map›Paper›PMID 42876699›Full record

ArticleFrontiers in cellular and infection microbiology2026

Fingolimod potentiates minocycline against multidrug-resistant

Jie Sun, Qiang Feng, Can Yang, Yulong Zong, Rongliang Gao, Li Shen, Fangyou Yu, Yongpeng Shang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jie Sun *Department of Clinical Laboratory, The Affiliated Taian City Central Hospital of Qingdao University, Taian, China.
Qiang Feng *Department of Clinical Laboratory, The Affiliated Taian City Central Hospital of Qingdao University, Taian, China.
Can YangDepartment of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Yulong ZongDepartment of Clinical Laboratory, The Affiliated Taian City Central Hospital of Qingdao University, Taian, China.
Rongliang GaoDepartment of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Li ShenDepartment of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Fangyou YuDepartment of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Yongpeng ShangDepartment of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Methods: Sixteen residual clinical isolates were examined. Baseline single-agent susceptibility was assessed by a single disk-diffusion determination and by VITEK 2. Fingolimod MIC and MBC values were measured by broth microdilution. Biofilm formation was quantified by crystal violet staining. Fingolimod-minocycline interactions were evaluated by checkerboard and time-kill assays. Preliminary protective activity was examined in a Results: Disk diffusion and VITEK 2 showed method-dependent discordance for piperacillin-tazobactam. Fifteen of 16 isolates formed biofilm; 13 of these 15 were weak and two were moderate producers. Fingolimod MICs ranged from 6.25 to 25 μg/mL. Fingolimod reduced the minocycline MIC by 4-8-fold in six synergistic isolates. The combination produced preliminary, isolate-specific protection in Conclusion: Fingolimod exhibits antibacterial activity against

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialDrug SynergismFingolimod HydrochlorideFlavobacteriaceaeMinocyclineAnimalsBiofilmsDisease Models, AnimalFlavobacteriaceae InfectionsHumansMicrobial Sensitivity TestsMothsAnti-Bacterial AgentsFingolimod HydrochlorideMinocyclinedrug repurposingElizabethkingia speciesfingolimodminocyclinesynergy

Identifiers

PMID42876699
PMCPMC13661465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.